Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Pipeline Review, H1 2016

  • ID: 3775422
  • Report
  • 87 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Johnson & Johnson
  • Medgenics, Inc.
  • Novartis AG
  • MORE
Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Pipeline Review, H1 2016

Summary

‘Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Pipeline Review, H1 2016’, provides in depth analysis on Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) targeted pipeline therapeutics.

The report provides comprehensive information on the Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5)
- The report reviews Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Johnson & Johnson
  • Medgenics, Inc.
  • Novartis AG
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) Overview

Therapeutics Development

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Products under Development by Stage of Development

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Products under Development by Therapy Area

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Products under Development by Indication

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Products under Development by Companies

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Products under Development by Universities/Institutes

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Confluence Pharmaceuticals LLC

Eisai Co., Ltd.

Eli Lilly and Company

Heptares Therapeutics Limited

Hua Medicine (Shanghai) Ltd.

Johnson & Johnson

Medgenics, Inc.

Merz Pharma GmbH & Co. KgaA

Novartis AG

Sumitomo Dainippon Pharma Co., Ltd.

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Drug Profiles

acamprosate calcium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alloswitch-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dipraglurant ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dipraglurant IR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DSR-98776 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fasoracetam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GET-73 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-14242 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-46778212 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LSN-2463359 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LSN-2814617 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mavoglurant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MRZ-8676 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize mGlu5 for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize mGluR5 and mGluR6 for Neurological Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize mGluR5 for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target mGluR5 for Schizophrenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0092273 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0431316 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0463841 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0467558 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Dormant Projects

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Discontinued Products

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Featured News & Press Releases

Jun 02, 2016: Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society

Apr 11, 2016: Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers

Mar 15, 2016: Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers

Jan 11, 2016: Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept

Jan 04, 2016: Addex’ Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease

Dec 17, 2015: Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial

Aug 14, 2015: Addex Dipraglurant Demonstrates Anxiolytic- and Antidepressant-like Activity in Multiple Preclinical Models Relevant for Non-Motor Symptoms in Parkinson’s disease

Jul 22, 2015: Addex Dipraglurant Dosed in First Subject in Receptor Occupancy Study in Collaboration with Johns Hopkins University and with Funding from The Michael J. Fox Foundation

Feb 23, 2015: Addex Initiates Dipraglurant Receptor Occupancy Clinical Study in Collaboration with Johns Hopkins University with Funding from The Michael J. Fox Foundation

Jan 19, 2015: Addex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia

Sep 04, 2013: Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1

May 01, 2013: Addex's Dipragluant Demonstrates Dose-dependent mGlu5 Receptor Occupancy In Non-human Primate PET Study

Apr 22, 2013: Addex Obtains European Composition Of Matter Patent Covering Dipraglurant And Other mGlu5 Negative Allosteric Modulators

Apr 18, 2013: Addex's Dipraglurant Normalizes Striatal Cholinergic Dysfunction In Validated Preclinical Model Of Primary Generalized Torsion Dystonia 1

Mar 21, 2013: Addex Therapeutics Announces Presentation On Dipraglurant Phase IIa Study Results At 2013 Annual Meeting Of American Academy Of Neurology

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Addex Therapeutics Ltd, H1 2016

Pipeline by Confluence Pharmaceuticals LLC, H1 2016

Pipeline by Eisai Co., Ltd., H1 2016

Pipeline by Eli Lilly and Company, H1 2016

Pipeline by Heptares Therapeutics Limited, H1 2016

Pipeline by Hua Medicine (Shanghai) Ltd., H1 2016

Pipeline by Johnson & Johnson, H1 2016

Pipeline by Medgenics, Inc., H1 2016

Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2016

Pipeline by Novartis AG, H1 2016

Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Dormant Projects (Contd..2), H1 2016

Dormant Projects (Contd..3), H1 2016

Discontinued Products, H1 2016

Discontinued Products (Contd..1), H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Johnson & Johnson
  • Medgenics, Inc.
  • Novartis AG
  • MORE
Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) pipeline Target constitutes close to 24 molecules. Out of which approximately 17 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Metabotropic Glutamate Receptor 5 – Pipeline Review, H1 2016, outlays comprehensive information on the Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling activates a phosphatidylinositol calcium second messenger system and generates a calcium activated chloride current. mGluR5 plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 1, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Addex Therapeutics Ltd
Confluence Pharmaceuticals LLC
Eisai Co., Ltd.
Eli Lilly and Company
Heptares Therapeutics Limited
Hua Medicine (Shanghai) Ltd.
Johnson & Johnson
Medgenics, Inc.
Merz Pharma GmbH & Co. KgaA
Novartis AG
Sumitomo Dainippon Pharma Co., Ltd.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll